GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: ATryn downstream processing (corrected)

According to Tom Newberry, GTC is satisfied with the downstream processing that Lonza is doing at its Hopkinton, MA facility for ATryn in the HD indication (#msg-21443058, #msg-22191984).

However, the volume of bulk material to be processed for ATryn in the DIC indication is expected to be much larger because DIC is a much larger addressable market than HD (#msg-22017312). Thus, GTC is inquiring about various contract-manufacturing arrangements for the DIC indication and a decision on whom to engage has not yet been made. [Correction: in a prior post, I wrongly implied that Lonza would not be employed by GTC for the DIC indication.]